Physician profile
Grigoriy M Goldenberg
NPI 1093784837
$2,358.16
in general payments reported to CMS, 2019-2025
10 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $158 · 2021: $401 · 2022: $565 · 2023: $355 · 2024: $298 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,272.73 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $464.33 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $301.24 | 2019-2021 | |
| Amgen INC. | $76.86 | 2022-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $68.64 | 2020-2022 | |
| Abbvie INC. | $58.17 | 2022-2024 | |
| Ardelyx, INC. | $34.12 | 2025 | Ibsrela |
| Allergan, INC. | $33.14 | 2019 | |
| Nestle Healthcare Nutrition INC. | $24.76 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $24.17 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grigoriy Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.